Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal ad… Read more
Market Cap & Net Worth: Panbela Therapeutics Inc (PBLA)
Panbela Therapeutics Inc (NASDAQ:PBLA) has a market capitalization of $1.67 Million ($1.67 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #34944 globally and #11393 in its home market, demonstrating a 4.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Panbela Therapeutics Inc's stock price $0.34 by its total outstanding shares 4854830 (4.85 Million).
Panbela Therapeutics Inc Market Cap History: 2015 to 2025
Panbela Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $4.85 Trillion to $1.67 Million (-78.52% CAGR).
Panbela Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Panbela Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-5214.05x
Panbela Therapeutics Inc's market cap is -5214.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $8.54 Billion | $-1.64 Million | -$34.93 Million | -5214.05x | N/A |
Competitor Companies of PBLA by Market Capitalization
Companies near Panbela Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Panbela Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Panbela Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Panbela Therapeutics Inc's market cap moved from $4.85 Trillion to $ 1.67 Million, with a yearly change of -78.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.67 Million | +0.88% |
| 2024 | $1.65 Million | -98.14% |
| 2023 | $88.84 Million | -98.96% |
| 2022 | $8.54 Billion | -95.76% |
| 2021 | $201.58 Billion | -51.40% |
| 2020 | $414.80 Billion | -15.24% |
| 2019 | $489.37 Billion | +20.00% |
| 2018 | $407.81 Billion | -65.00% |
| 2017 | $1.17 Trillion | -42.53% |
| 2016 | $2.03 Trillion | -58.24% |
| 2015 | $4.85 Trillion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Panbela Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.67 Million USD |
| MoneyControl | $1.67 Million USD |
| MarketWatch | $1.67 Million USD |
| marketcap.company | $1.67 Million USD |
| Reuters | $1.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.